Selected Publications

Reviews on SHIP

Rauh, M. J., Sly, L. M., Kalesnikoff, J., Hughes, M. R., Cao, L. P., Lam, V., and Krystal, G. (2004). The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans 32, 785-788.

March, M. E., and Ravichandran, K. (2002). Regulation of the immune response by SHIP. Semin Immunol 14, 37-47.

Kalesnikoff, J., Lam, V., and Krystal, G. (2002). SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival. Mol Immunol 38, 1201-1206.

Krystal, G. (2000). Lipid phosphatases in the immune system. Semin Immunol 12(4): 397-403.

Selected Papers on SHIP

Haddon, D. J., F. Antignano, et al. (2009). SHIP1 Is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo. J Immunol 183(1): 228-36.

Helgason, C. D., Damen, J. E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S. M., Borowski, A., Jirik, F., Krystal, G., and Humphries, R. K. (1998). Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12, 1610-1620.

Rauh, M. J., Ho, V., Pereira, C., Sham, A., Sly, L. M., Lam, V., Huxham, L., Minchinton, A. I., Mui, A., and Krystal, G. (2005). SHIP represses the generation of alternatively activated macrophages. Immunity 23, 361-374.

Sly, L. M., Rauh, M. J., Kalesnikoff, J., Song, C. H., and Krystal, G. (2004). LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21, 227-239.

Huber, M., Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K., and Krystal, G. (1998). The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci USA 95, 11330-11335.

Ong, C. J., Ming-Lum, A., Nodwell, M., Ghanipour, A., Yang, L., Williams, D. E., Kim, J., Demirjian, L., Qasimi, P., Ruschmann, J., Cao, L., Ma, K., Chung, S. W., Duronio, V., Andersen, R. J., Krystal, G., and Mui, A. (2007). Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110(6), 1942-1949.

Ganesan, L. P., T. Joshi, et al. (2006). FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood 108(2): 718-25.

Kalesnikoff, J., N. Baur, et al. (2002). SHIP negatively regulates IgE + antigen-induced IL-6 production in mast cells by inhibiting NF-kappa B activity. J Immunol 168(9): 4737-46.

Kamata, T., M. Yamashita, et al. (2003). src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 111(1): 109-19.

Liu, Q., F. Shalaby, et al. (1998). The SH2-containing inositol polyphosphate 5-phosphatase, ship, is expressed during hematopoiesis and spermatogenesis. Blood 91(8): 2753-9.

Oh, S. Y., T. Zheng, et al. (2007). Src homology 2 domain-containing inositol 5-phosphatase 1 deficiency leads to a spontaneous allergic inflammation in the murine lung. J Allergy Clin Immunol 119(1): 123-31.

Ooms, L. M., K. A. Horan, et al. (2009). The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem J 419(1): 29-49.

Vonakis, B. M., S. Gibbons, Jr., et al. (2001). Src homology 2 domain-containing inositol 5' phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 108(5): 822-31.

Chemistry Paper on Aquinox Compounds and Analogues

Yang, L., Williams, D. E., Mui, A., Ong, C., Krystal, G., van Soest, R., and Andersen, R. J. (2005). Synthesis of pelorol and analogues: activators of the inositol 5-phosphatase SHIP. Org Lett 7, 1073-1076.

Review on PI3K Pathway and Cancer Drug Discovery

Harris, S. J., Parry, R.V., Westwick, J., and Ward, S. G. (2008). Phosphoinositide Lipid Phosphatases: Natural Regulators of Phosphoinositide 3-Kinase Signaling in T Lymphocytes. J Bio Chem 283(5), 2465-2469.

Crabbe, T., Welham, M. J., and Ward, S. G. (2007). The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci 32(10), 450-456.

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988-1004.

Cully, M., You, H., Levine, A. J., and Mak, T. W. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6, 184-192.

Firestein, G. S. (2006). Inhibiting inflammation in rheumatoid arthritis. N Engl J Med 354(1): 80-2.

Ruckle, T., M. K. Schwarz, et al. (2006). PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 5(11): 903-18.

Selected Papers on PI3K

Ali, K., M. Camps, et al. (2008). Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180(4): 2538-44.

Ito, K., G. Caramori, et al. (2007). Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321(1): 1-8.

Lee, K. S., H. K. Lee, et al. (2006). Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 20(3): 455-65.